CRP and non-small cell lung carcinoma: GPS is based on a combination of CRP and albumin and has been evaluated in a variety of cancers, such as renal cancer, breast cancer, non-small cell lung cancer, gastroesophageal cancer, pancreatic cancer, and colorectal cancer [19-24].